Teleflex Incorporated

NYSE:TFX

Medical - Instruments & Supplies

Healthcare
$165.85 +0.83%

+$1.04 today

Market cap
$6.58B
Beta
0.82
P/E (TTM)
-5.5
EPS (TTM)
-$22.79
Dividend yield
1.08%
52W Low $100.18High $139.67

Volume 1.16M

Average 0.80M

TFX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Teleflex IncorporatedNYSE: TFX

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $5.44M fell 21.6% year over year, ahead of the -33.5% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 19.3% from the prior quarter.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -21.6% holds above the trailing-twelve-month pace of -33.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.44M-19.3% QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$20.21M-33.5% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.6%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Stock-Based Compensation vs competitors

How TFX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -33.5% is the 8th highest of 10, against a peer median of +5.4%.
  • Stock-based compensation amounts to 0.8% of revenue for TFX, versus a peer median of 8.4%.
TFX Competitors
Stock-Based Compensation for TFX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PCVXVaxcyte, Inc.LTM Jun 2026$188.47M USD+66.5%+80.4%—
TGTXTG Therapeutics, Inc.LTM Sep 2026$88.18M USD+44.6%+49.9%9.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M USD+15.0%-12.3%8.4%
BLCOBausch + Lomb CorporationLTM Jun 2026$72M USD-33.9%+33.9%1.4%
CRSPCRISPR Therapeutics AGLTM Sep 2026$69.68M USD-8.8%-9.5%276.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$68.15M USD+7.5%-4.5%15.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$45.39M USD+5.4%+34.1%2.8%
KRYSKrystal Biotech, Inc.LTM Jun 2026$41.53M USD-23.5%+17.9%9.4%
ALKSAlkermes plcLTM Sep 2026$21.78M USD-76.6%+1.6%1.2%
TFXTeleflex IncorporatedLTM Jun 2026$20.21M USD-33.5%—0.8%
STVNStevanato Group S.p.A.LTM Jun 2026€0 EUR——0.0%
Peer median (excluding TFX) —+5.4%+17.9%8.4%

Competitors are the stored peer set for TFX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income485.37M363.14M356.33M69.68M58.53M
Depreciation & Amortization237.36M230.59M242.12M274.6M177.74M
Deferred Income Tax(110.24M)(13.01M)(13.05M)0(100.97M)
Stock-Based Compensation22.94M27.22M31.47M31.35M0
Change in Working Capital127.35M(239.96M)(111.77M)(1.82M)(81.09M)
Accounts Receivables(600K)(38.46M)(15.76M)(27.95M)(85.53M)
Inventory(11.14M)(110.69M)(41.07M)1.72M84.04M
Accounts Payables94.02M(24.79M)(31.26M)9.67M(8.28M)
Other Working Capital45.06M(66.03M)(23.68M)14.74M(71.31M)
Other Non-Cash Items(111.36M)(25.84M)5.55M261.94M286.46M
Operating Cash Flow651.42M342.14M510.64M635.74M340.68M
Capital Expenditures(71.62M)(79.19M)(91.44M)(126.43M)(95.24M)
Acquisitions (Net)220.32M(186M)(588.92M)(120K)(825.15M)
Purchases of Investments(18.42M)(22.3M)(11.3M)(7.3M)(5M)
Sales of Investments7.3M7.3M7.3M7.3M0
Other Investing Activities19.15M22.24M63.13M27.2M76.19M
Investing Cash Flow156.74M(257.94M)(621.23M)(99.36M)(849.19M)
Debt Repayment(634.5M)(145.45M)101.25M(161.5M)982.04M
Common Stock Issued11.1M4.31M000
Common Stock Repurchased0(4.31M)0(200M)(300M)
Dividends Paid(63.65M)(63.79M)(63.9M)(63.54M)(60.27M)
Other Financing Activities(28.77M)(8.27M)1.19M3.12M(10.23M)
Financing Cash Flow(715.82M)(217.51M)38.54M(421.93M)611.54M
Effect of Forex Changes(23.13M)(19.74M)2.86M(9.65M)(29.35M)
Net Change in Cash69.2M(153.05M)(69.19M)104.8M73.68M
Free Cash Flow579.8M262.95M419.2M509.31M245.44M

Teleflex Incorporated

NYSE:TFX

Intrinsic Alpha fair value

Locked

Current Price

$165.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.